Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

UNKNOWN 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Gastrointestinal 1Endocrine 1

Conditions

Colorectal Neoplasms 1295Pancreatic Neoplasms 819Carcinoma, Hepatocellular 782Stomach Neoplasms 754Rectal Neoplasms 565Esophageal Neoplasms 452Colonic Neoplasms 414Esophageal Squamous Cell Carcinoma 277Neoplasm Metastasis 263Cholangiocarcinoma 251Liver Neoplasms 219Neoplasms 200Biliary Tract Neoplasms 179Adenocarcinoma Of Esophagus 139Gastrointestinal Stromal Tumors 108Gallbladder Neoplasms 96Adenocarcinoma 94Breast Neoplasms 91Gastrointestinal Neoplasms 89Carcinoma, Non-Small-Cell Lung 87Bile Duct Neoplasms 69Sarcoma 67Lung Neoplasms 64Ovarian Neoplasms 60Anus Neoplasms 59Melanoma 54Uterine Cervical Neoplasms 52Carcinoma 48Digestive System Neoplasms 45Prostatic Neoplasms 40

Interventions

Thalidomide 1Temozolomide 1Tegafur 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Extrapancreatic Neuroendocrine Tumor × Gastrointestinal × Clear all
NCT03204032 2017-06-29

A Study of Tegafur Combined With Temozolomide Versus Tegafur Combined With Temozolomide and Thalidomide in Subjects With Advanced Extrapancreatic Neuroendocrine Tumor

ChineseAMS

Phase 2 Unknown
60 enrolled
EndocrineGastrointestinalNET

Extrapancreatic Neuroendocrine Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡